| Latest Watson Pharmaceuticals News Headlines | | Date | Time | Source | | | 11/16/2009 | 7:00AM | PRNUS | Watson Names Robert A. Stewart Senior Vice President, Global Operations
Restructures to Create Global Operations, Global Generics Commercial Functions
MORRISTOWN, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE:WPI) today announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately... More...>> |
| 11/10/2009 | 9:12PM | PRNUS | Watson Announces Presentation Time Change at Credit Suisse Healthcare Conference
MORRISTOWN, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today a change for the Company's presentation at the Credit Suisse 18th Annual Healthcare Conference scheduled for Wednesday, November 11, 2009. Watson's presentation will... More...>> |
| 11/04/2009 | 7:30AM | PRNUS | Watson Reports Third Quarter 2009 GAAP EPS of $0.55; Adjusted EPS of $0.66
MORRISTOWN, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) today reported net income of $63.0 million, or $0.55 per diluted share for the third quarter ended September 30, 2009. Excluding special items as detailed in the reconciliation table below, adjusted net income for the third quarter... More...>> |
| 10/30/2009 | 7:30AM | PRNUS | Watson Names R. Todd Joyce Senior Vice President and Chief Financial Officer; Succeeds Mark W. Durand
MORRISTOWN, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE:WPI) today announced that R. Todd Joyce has been named Senior Vice President and Chief Financial Officer (CFO) effective immediately. Mr. Joyce succeeds Mark W. Durand, who has departed as CFO for personal reasons. On July 27, 2009, Watson... More...>> |
| 09/29/2009 | 7:50AM | PRNUS | New Data Suggest that GELNIQUE(R) (oxybutynin chloride) gel 10% Does Not Impact Cognition among Healthy Older Adults
- Previous research suggests oral oxybutynin formulations can impair cognition -
SAN FRANCISCO, Sept. 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leader in generic and specialty branded pharmaceuticals, announced findings of a double-blind study which demonstrate that GELNIQUE was comparable... More...>> |
| 08/18/2009 | 5:09PM | PRNUS | Watson Prices $850 Million of Senior Unsecured Notes
MORRISTOWN, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a specialty pharmaceutical company, today announced the pricing of a debt offering of $450.0 million of 5.000% senior notes due 2014 and $400.0 million of 6.125% senior notes due 2019, for a total offering of $850.0 million... More...>> |
| 08/18/2009 | 9:01AM | PRNUS | Watson Announces Offering of Senior Unsecured Notes
MORRISTOWN, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a specialty pharmaceutical company, today announced that it is offering up to $850 million aggregate principal amount of five and ten year senior unsecured notes in a registered public offering.
Watson intends to use the net... More...>> |
| 08/07/2009 | 5:01PM | PRNUS | Watson Announces Limited Recall Of Fentanyl Transdermal System
MORRISTOWN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies. The recalled... More...>> |
| 08/06/2009 | 6:08PM | PRNUS | Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
MORRISTOWN, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of privately held... More...>> |
| 07/29/2009 | 7:05AM | PRNUS | Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
MORRISTOWN, N.J., July 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leader in generic and specialty branded pharmaceuticals, today reported net income of $53.0 million, or $0.46 per diluted share. Excluding special items as detailed in the reconciliation table below, adjusted net income for... More...>> |
| 07/15/2009 | 8:00AM | PRNUS | Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
- Paragraph IV Litigation Underway -
MORRISTOWN, N.J., July 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida ("Watson"), has filed an Abbreviated New Drug Application (ANDA) with the... More...>> |
| 07/14/2009 | 7:45AM | PRNUS | Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA
- Company to Address Agency Requests in a Timely Manner -
MORRISTOWN, N.J., July 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug... More...>> |
| 07/10/2009 | 8:05AM | PRNUS | Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
MORRISTOWN, N.J., July 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that it has resumed shipments to reintroduce its intravenous iron replacement therapy INFeD (iron dextran injection,USP). The product, which had been out of stock... More...>> |
| 07/10/2009 | 8:00AM | PRNUS | Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
MORRISTOWN, N.J., July 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, announced today that the Company intends to release its second quarter 2009 financial results on Wednesday, July 29, 2009 prior to the open of the U.S. financial markets. The Company... More...>> |
| 06/24/2009 | 5:48PM | PRNUS | Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
MORRISTOWN, N.J., June 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application... More...>> |
| 06/17/2009 | 7:30AM | PRNUS | Watson to Acquire Arrow Group
- Arrow Will Expand Watson's Global Commercial Footprint
MORRISTOWN, N.J., June 17 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and... More...>> |
| 06/10/2009 | 6:45AM | PRNUS | Watson Files FDA Application for Generic Mucinex(R) D
- Paragraph IV Litigation Underway -
CORONA, Calif., June 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food... More...>> |
| 05/21/2009 | 7:50AM | PRNUS | Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
- Bold and innovative marketing campaign will target women and highlight product's efficacy, ease of use and excellent tolerability -
CORONA, Calif., May 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals, announced today the launch of GELNIQUE(TM) (oxybutynin... More...>> |
| 05/18/2009 | 9:30AM | PRNUS | Watson Provides Update on Ferrlecit(R) Supply and Distribution Agreement
Watson to Market and Sell Ferrlecit(R) through December 31, 2009
CORONA, Calif., May 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, today announced that the Swiss Chambers of Commerce Court of Arbitration has ruled that the Ferrlecit(R) (sodium ferric... More...>> |
| 05/08/2009 | 7:50AM | PRNUS | RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Day
- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data -
CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO(TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both... More...>> |
|